Diabetes Atherosclerosis Intervention Study (DAIS)

(Redirected from DAIS)
Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

Diabetes Atherosclerosis Intervention Study (DAIS) On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Diabetes Atherosclerosis Intervention Study (DAIS)

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Diabetes Atherosclerosis Intervention Study (DAIS)

CDC on Diabetes Atherosclerosis Intervention Study (DAIS)

Diabetes Atherosclerosis Intervention Study (DAIS) in the news

Blogs on Diabetes Atherosclerosis Intervention Study (DAIS)

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for Diabetes Atherosclerosis Intervention Study (DAIS)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Overview

The Diabetes Atherosclerosis Intervention Study (DAIS) is a double-blinded placebo-controlled study that assessed the rate of cardiovascular disease following the administration of 200 mg fenofibrate in non-insulin-dependent diabetes subjects.[1]

References

  1. Steiner G (1996). "The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group". Diabetologia. 39 (12): 1655–61. PMID 9081851.